Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03364348
Title 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors George W. Sledge Jr.
Indications

Her2-receptor positive breast cancer

Therapies

Trastuzumab + Utomilumab

Ado-trastuzumab emtansine + Utomilumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.